Astrazeneka and BenevolentAI started the joint project for acceleration of process of search of medicines

On May 13, 2019 the Astrazeneka company announced start with BenevolentAI company of the long-term joint project which means use of machine learning technologies and the artificial intelligence (AI) for the purpose of search and development of new medicines for treatment of the chronic disease of kidneys (CDK) and the idiopathic pulmonary fibrosis (IPF).

Scientists of both companies will carry out joint work for the purpose of consolidation of the data concerning genomics, chemicals and a clinical picture of the diseases which are saved up by Astrazeneka company with belonging to BenevolentAI company the platform for selection of a specific object of studying and the column of biomedical knowledge – the network of kontekstualizirovanny scientific data (about genes, proteins, diseases and chemical compounds) reflecting interrelation between them.

By means of machine learning technologies permanent data analysis for the purpose of identification of interrelation between discrete facts is carried out, and the logical constructions based on use of AI technologies are applied to studying of earlier unknown interrelations. Joint interpretation of results will allow to understand development mechanisms of these difficult diseases and to reduce time necessary for search of new possible targets of therapy.

"The number of data available to the scientist-researchers, hugely and exponential increases every year. By means of consolidation of big and various data arrays and also knowledge and experience which are saved up by Astrazeneka company in the field of studying of diseases with the advanced developments of "BenevolentAI" in the field of artificial intelligence and machine learning, we will be able to open possibilities of this huge number of accumulated information for improvement of our understanding of difficult biological development mechanisms of a disease and determination of new targets which will help to cure the disabling diseases". Mene Pangalos, executive vice president and president of the direction of research and development of biological medicines

"In the modern world millions of people have diseases for which effective methods of treatment are not developed yet. The future of search and development of medicines consists in consolidation of AI technologies, the saved-up these and biological processes. We are glad that we managed to combine efforts with Astrazeneka company for obtaining unique information and development of new perspective approaches to treatment of a chronic disease of kidneys and idiopathic pulmonary fibrosis". Joanna Shields, chief executive of BenevolentAI company

HBP and ILF are multiple-factor diseases which pathogenesis is not clear. The complexity of these diseases requires the analysis of a large number of volume data arrays.